Chemical components of var. and their cytotoxic and antibacterial activities.

Nineteen compounds, including seventeen alkaloids O-methylarmepavine (), (S)-6-methoxy-1-(4-methoxybenzyl)-2-methyl -1,2,3,4-tetrahydroisoquinolin-7-ol (), (+)-(IR,laR)-lahydroxymagnocurarin (), (6R,6aS,P)-(+)-corydine (), (+)-N-methyllaurotetanine (), magnoflorine (), 3-hydroxy-1,2-dimethoxy-5-methyl-5H-dibenzoindol-4-one (), imperialine (), crispine B (), (S)-1-(3-methoxyphenyl)-N-methylpropan-2-amine (), methyl 2- (acetamino)benzoate (), 2-carboxyoxanilic acid methylester (), 4-[2-(methoxycarbonyl) anilino]-4-oxobutanoic acid methyl ester (), N-methylcorydaldine (), N-methyl-6,7- dimethoxyisoquinolone (), (5,6,7,8)-5-amino-(2Z,4Z)-1,2,3-trihybuta-2,4-dienyloxypentane- 6,7,8,9-tetraol (), nicotinic acid (), and two megastigmane type compounds, S(+)- dehydrovomifoliol () and megastigmane (), were isolated from the Aconitum barbatum var. puberulum Ledeb. Compounds and were isolated from this plant for the first time, of which compound was isolated from natural source for the first time.

Diterpenoid alkaloids from Aconitum barbatum var. puberulum Ledeb.

Seven previously undescribed diterpenoid alkaloids, including five C-diterpenoid alkaloids, barpuberudine, barpubesines A-D, and two C-diterpenoid alkaloids, barpubenines A-B, along with 11 known diterpenoid alkaloids were isolated from the whole plant of Aconitum barbatum var. puberulum Ledeb. (Ranunculaceae).

Optimal timing of bisphosphonate administration in combination with samarium-153 oxabifore in the treatment of painful metastatic bone disease.

While bisphosphonates are indicated for prevention of skeletal-related events, radionuclide therapy is widely used for treatment of painful bone metastases. Combined radionuclide therapy with bisphosphonates has demonstrated improved effectiveness in achieving bone pain palliation in comparison to mono therapy with radionuclides or bisphosphonates alone. However, there are conflicting reports as to whether bisphosphonates adversely influence skeletal uptake of the bone-seeking radiotracers used for therapy.